New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:47 EDTEPZMEpizyme price target raised to $52 from $37 at Wedbush
Wedbush increased its price target on Epizyme after the company released clinical data on its EPZ-5676 treatment that the firm views as positive. The firm reiterates an Outperform rating on the stock.
News For EPZM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 8, 2016
08:01 EDTEPZMEpizyme says tazemetostat granted orphan drug designation by FDA
Subscribe for More Information
February 7, 2016
14:13 EDTEPZMEpizyme's tazemetostat receives orphan designation for malignant rhabdoid tumors
Subscribe for More Information
February 2, 2016
07:15 EDTEPZMCanaccord to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use